NASDAQ:TNGX Tango Therapeutics (TNGX) Stock Price, News & Analysis $6.98 +0.08 (+1.16%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Tango Therapeutics Stock (NASDAQ:TNGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tango Therapeutics alerts:Sign Up Key Stats Today's Range$6.83▼$7.1450-Day Range$6.90▼$11.9352-Week Range$5.15▼$13.03Volume448,455 shsAverage Volume745,934 shsMarket Capitalization$745.79 millionP/E RatioN/ADividend YieldN/APrice Target$15.14Consensus RatingBuy Company OverviewTango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.Read More… Next opportunity for crypto millions (Ad)The floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine… Go here to discover the crypto that's about to leave Wall Street in the dust. Tango Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks32nd Percentile Overall ScoreTNGX MarketRank™: Tango Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 781st out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingTango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTango Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Tango Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tango Therapeutics are expected to decrease in the coming year, from ($1.27) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tango Therapeutics is -6.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tango Therapeutics is -6.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTango Therapeutics has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tango Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.11% of the float of Tango Therapeutics has been sold short.Short Interest Ratio / Days to CoverTango Therapeutics has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Tango Therapeutics has recently increased by 2.35%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTango Therapeutics does not currently pay a dividend.Dividend GrowthTango Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.11% of the float of Tango Therapeutics has been sold short.Short Interest Ratio / Days to CoverTango Therapeutics has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Tango Therapeutics has recently increased by 2.35%, indicating that investor sentiment is decreasing. News and Social Media1.5 / 5News Sentiment0.62 News SentimentTango Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Tango Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for TNGX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tango Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,042,393.00 in company stock.Percentage Held by InsidersOnly 6.20% of the stock of Tango Therapeutics is held by insiders.Percentage Held by Institutions78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tango Therapeutics' insider trading history. Receive TNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TNGX Stock News HeadlinesTango Therapeutics, Inc. (NASDAQ:TNGX) Major Shareholder Rock Ventures Iv L.P. Third Sells 67,400 SharesSeptember 18, 2024 | insidertrades.comTango Therapeutics, Inc. (NASDAQ:TNGX) Major Shareholder Rock Ventures Iv L.P. Third Sells 75,000 SharesSeptember 10, 2024 | insidertrades.comNext opportunity for crypto millionsOctober isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere…October 6, 2024 | Crypto 101 Media (Ad)Tango Therapeutics (NASDAQ:TNGX) Stock Quotes, Forecast and News SummaryOctober 5 at 1:29 AM | benzinga.comTango Therapeutics, Inc. (NASDAQ:TNGX) Receives $15.14 Average Price Target from BrokeragesSeptember 29, 2024 | americanbankingnews.comTango Therapeutics: A Buy Rating Amidst Competitive Advantages and Promising Market ValuationSeptember 11, 2024 | markets.businessinsider.comTango Therapeutics maintains stock target, Overweight rating on latest dataSeptember 11, 2024 | investing.comThird Rock Ventures sells $867k of Tango Therapeutics stockSeptember 11, 2024 | investing.comSee More Headlines TNGX Stock Analysis - Frequently Asked Questions How have TNGX shares performed this year? Tango Therapeutics' stock was trading at $9.90 at the beginning of the year. Since then, TNGX shares have decreased by 29.5% and is now trading at $6.98. View the best growth stocks for 2024 here. How were Tango Therapeutics' earnings last quarter? Tango Therapeutics, Inc. (NASDAQ:TNGX) posted its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.34) by $0.10. The business earned $19.88 million during the quarter, compared to the consensus estimate of $7.39 million. Tango Therapeutics had a negative trailing twelve-month return on equity of 44.73% and a negative net margin of 274.04%. Who are Tango Therapeutics' major shareholders? Tango Therapeutics' top institutional shareholders include SG Americas Securities LLC (0.02%). Insiders that own company stock include Rock Ventures Iv LP Third, Boxer Capital, Llc, Mva Investors, Llc, Daniella Beckman and Douglas Barry. View institutional ownership trends. How do I buy shares of Tango Therapeutics? Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/07/2024Today10/06/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNGX CUSIPN/A CIK1819133 Webwww.tangotx.com Phone857-320-4900FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$15.14 High Stock Price Target$19.00 Low Stock Price Target$13.00 Potential Upside/Downside+116.9%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,740,000.00 Net Margins-274.04% Pretax Margin-273.63% Return on Equity-44.73% Return on Assets-28.79% Debt Debt-to-Equity RatioN/A Current Ratio7.49 Quick Ratio7.49 Sales & Book Value Annual Sales$42.51 million Price / Sales17.54 Cash FlowN/A Price / Cash FlowN/A Book Value$2.48 per share Price / Book2.81Miscellaneous Outstanding Shares106,846,000Free Float100,222,000Market Cap$745.79 million OptionableOptionable Beta0.81 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:TNGX) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | Sponsored[SHOCKING] Crypto Document Leak…A shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.